OverT Bio

Excited to share a big milestone for OverT Bio—we’ve formed our Clinical Advisory Board. Grateful to partner with an incredible group of leaders as we build scalable γδ CAR-T therapies for solid tumors. businesswire.com/news/home/2026…

One more biotech coming out of stealth! OverT Bio debuts with $16M to find new ways to make solid cancer cell therapies. Read it here: endpts.com/overt-bio-debu… @OverT_Bio

Congrats to @MatLegut & the entire @OverT_Bio team! Grateful for the opportunity to translate discoveries from our lab @nygenome & @nyuniversity into therapies for cancer patients. Thrilled to be a part of this amazing team — onward and upward! 🚀

Grateful to @artisventures, @wing_vc, and all our investors. Shout-out to early believers @vasudevbailey and @sarachoi_ and the founding team @nevillesanjana and @matlegut

How? We screen tens of thousands of genetic enhancements and receptors to build the optimal therapeutic cells. Our decisions are guided by data, not assumptions. overt.bio/home/science

We're thrilled to launch OverT Bio! Debuting with $16M of initial financing, we will develop safe and effective #celltherapies for solid tumor cancers. endpts.com/overt-bio-debu…